ABO 202Alternative Names: AAV-CLN1 - Abeona Therapeutics; ABO-202
Latest Information Update: 29 Sep 2016
At a glance
- Originator University of North Carolina at Chapel Hill
- Developer Abeona Therapeutics; University of North Carolina at Chapel Hill
- Class Gene therapies
- Mechanism of Action Gene transference
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Preclinical Neuronal ceroid lipofuscinosis